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Abstract
Oxidative stress and mitochondrial dysfunction have been described in Huntington’s disease, a 
disorder caused by expression of mutant huntingtin (mHtt). IGF-1 was previously shown to 
protect HD cells, whereas insulin prevented neuronal oxidative stress. In this work we analysed 
the role of insulin and IGF-1 in striatal cells derived from HD knock-in mice on mitochondrial 
production of reactive oxygen species (ROS) and related antioxidant and signaling pathways 
influencing mitochondrial function. Insulin and IGF-1 decreased mitochondrial ROS induced by 
mHtt and normalized mitochondrial SOD activity, without affecting intracellular glutathione 
levels. IGF-1 and insulin promoted Akt phosphorylation without changing the nuclear levels of 
phosphorylated Nrf2 or Nrf2/ARE activity. Insulin and IGF-1 treatment also decreased 
mitochondrial Drp1 phosphorylation, suggesting reduced mitochondrial fragmentation, and 
ameliorated mitochondrial function in HD cells in a PI-3K/Akt-dependent manner. This was 
accompanied by increased total and phosphorylated Akt, Tfam and mitochondrial-encoded 
cytochrome c oxidase II, as well as Tom20 and Tom40 in mitochondria of insulin- and IGF-1-
treated mutant striatal cells. Concomitantly, insulin/IGF-1-treated mutant cells showed reduced 
apoptotic features. Hence, insulin and IGF-1 improve mitochondrial function and reduce 
mitochondrial ROS caused by mHtt by activating the PI-3K/Akt signaling pathway, in a process 
independent of Nrf2 transcriptional activity, but involving enhanced mitochondrial levels of Akt 
and mitochondrial-encoded complex IV subunit.  
 
 
 
Abbreviations: Akt, protein kinase B; ARE, antioxidant responsive element; Erk, extracellular 
signal-regulated kinase; CBP, CREB-binding protein; CREB, cAMP response-element (CRE) 
binding protein; CDK (cyclin-dependent kinase);  DHE, dihydroethidium; Drp1, dynamin-related 
protein 1 or dynamin 1-like (DNM1L); GCL, glutamate-cysteine ligase; GCLc, glutamate-
cysteine catalytic subunit; GPx, glutathione peroxidase; GSH, glutathione, reduced form; GSSG, 
glutathione oxidized form; IGF-1, Insulin-like growth factor 1; IGF1R, insulin-like growth factor 
1 receptor; IR, insulin receptor; IRS, insulin receptor substrate; H2DCFDA, 2’,7’-
dichlorodihydrofluorescein diacetate; HKII, hexokinase type II; HD, Huntington’s disease; HO-1, 
heme oxygenase; Hsp60, heat shock 60kDa protein 1 (chaperonin); mHtt,  mutant huntingtin; 
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mtDNA, mitochondrial DNA; MT-COII, mitochondrial-encoded cytochrome c oxidase II; 
mTOR, mammalian target of rapamycin; NDUFS3, NADH dehydrogenase (ubiquinone) Fe-S 
protein 3, 30kDa (NADH-coenzyme Q reductase); NQO1, NAD(P)H dehydrogenase [quinone] 1; 
Nrf2, nuclear factor (erythroid-derived 2)-like 2; PI-3K, phosphatidylinositol 3-kinase; PGC-1, 
peroxisome proliferator-activated receptor- coactivator 1; ROS, reactive oxygen species; 
SDHA, succinate dehydrogenase complex, subunit A, flavoprotein (Fp); SOD, superoxide 
dismutase; Tfam, transcription factor A, mitochondrial; TMRM, tetramethylrhodamine methyl 
ester; Tom20, translocase of outer mitochondrial membrane 20 homolog (yeast); Tom40, 
translocase of outer mitochondrial membrane 40 homolog (yeast).  
Introduction 
Huntington’s disease (HD) is a progressive neurodegenerative disorder characterized by 
motor and psychiatric disturbances and cognitive decline leading to dementia. HD results from 
CAG repeat expansion in the HD gene, leading to increased polyglutamine tail at the N-terminal 
of huntingtin (Htt) [1]. The resultant mutant Htt (mHtt) causes striatal and cortical 
neurodegeneration, which has been linked to several pathological mechanisms, including 
excitotoxicity, proteasomal dysfunction, transcriptional deregulation, mitochondrial dysfunction, 
impaired energy metabolism and oxidative stress [2,3]. 
Several oxidative stress markers were previously observed in HD. Elevated levels of DNA 
oxidation were detected in blood plasma, serum and leukocytes from HD patients [4-6] and in 
striatum and cortex of HD post-mortem tissues [7-9]. DNA oxidation was also detected in the 
striatum, urine and plasma of R6/2 HD mice [10]. Increased lipid peroxidation markers were also 
detected in HD patient’s blood serum and plasma, correlating with disease severity [5, 11] in the 
striatum and cortex of post-mortem HD human brains [12,13] and in total brain and striatum of 
R6/2 mice, co-localizing with mHtt inclusions [13,14]. Moreover, intracellular aggregates of 
mHtt exon-1 were directly linked to increased production of reactive oxygen species (ROS), in a 
polyglutamine length-dependent manner, preceding cell death [15]. Impairment in antioxidant 
defenses also underlies oxidative stress in HD. In erythrocytes from HD patients, glutathione 
peroxidase (GPx) and superoxide dismutase 1 (SOD1 or Cu/Zn-SOD) activities were decreased 
[5]. Proteomic analysis of HD post-mortem striatal and cortical brain samples revealed the 
induction of peroxiredoxins 1, 2 and 6 and GPx 1 and 6, and increased activities of SOD2 (Mn-
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SOD) and catalase [16]. More recently, we demonstrated increased ROS formation and 
deregulated glutathione redox cycle in HD striatal cells [17].  
ROS formation in HD has been largely attributed to impaired mitochondrial function. 
Evidences for mitochondrial dysfunction in HD include, among other reports, decreased activity 
of mitochondrial complexes I-IV in caudate and putamen, and in muscle and platelets of HD 
patients [e.g. 18,19], reduced activities of complexes I, IV and V in progenitor and differentiated 
neuron-like STHdhQ111/Q111 cells [20], mitochondrial membrane depolarization and decreased 
mitochondrial Ca2+ retention [21,22]. STHdhQ111/Q111 striatal cells also showed high levels of 
mitochondrial ROS, mitochondrial DNA (mtDNA) damage and a lower spare respiratory 
capacity [23]. Treatment with a mitochondria-specific antioxidant improved mitochondrial 
function in HdhQ150 knock-in mice and restored mtDNA copy number to levels similar to the 
controls [24]. These results suggest oxidative stress-induced mitochondrial abnormalities 
following mHtt expression. Interaction of mHtt with the outer mitochondrial membrane was 
further demonstrated in mitochondria from YAC72 transgenic mice, STHdhQ111/Q111 striatal cells 
and in mouse liver mitochondria, causing the opening of the mitochondrial permeability 
transition pore [21,25]. 
Neuronal survival largely depends on growth factors through activation of kinases, namely 
the Ser/Thr protein kinase B (Akt). Insulin-like growth factor 1 (IGF-1) levels were decreased in 
HD mutant striatal cells, in human HD striatal post-mortem tissues and in plasma of 11 week-old 
R6/2 mice [26]. Moreover, IGF-1-mediated Akt activation was described to be neuroprotective in 
HD and to reduce nuclear inclusions through phosphorylation of mHtt at Ser421 [27]; activation 
of Akt was described to reflect early striatal pro-survival response in HD knock-in HdhQ111 mice 
and STHdhQ111/Q111 cells [28]. We previously reported that peripheral administration of IGF-1 
protected against HD-associated impaired glucose tolerance in R6/2 mice [29]. Furthermore, we 
recently showed that intranasal administration IGF-1 in YAC128 mice enhanced IGF-1 cortical 
levels, improved motor activity, activated Akt, enhanced mHtt phosphorylation at Ser421 and 
improved brain metabolic features [30]. Insulin, which shares structural and signaling properties 
with IGF-1, also protected against oxidative stress in cortical neurons through Akt activation 
[31]. Interestingly, in endothelial cells, insulin induced the expression of glutamate-cysteine 
ligase (GCL) catalytic subunit (GCLc) through the transcription factor nuclear factor (erythroid-
derived 2)-like 2 (Nrf2) [32], directly interfering with cellular antioxidant profile. Importantly, 
5 
 
impaired Nrf2 signaling pathway was recently described in striatal STHdhQ111/Q111 cells [33]. 
Interestingly, insulin/IGF-1-related signaling kinases, namely Akt and extracellular signal-
regulated kinase 1/2 (Erk1/2) were shown to translocate to the mitochondria and regulate several 
different proteins crucial to mitochondrial function. While Akt was described to promote 
enhanced mitochondrial function, Erk1/2 might conduce an opposite effect [e.g. 34-37]. 
In this work we examined the role of insulin and IGF-1 on mitochondrial ROS generation and 
mitochondrial membrane potential, and evaluated Nrf2 transcriptional activity related with 
antioxidant profile in HD knock-in striatal cells. We show that insulin and IGF-1 inhibit cellular 
Erk activation, increase Akt activation and Akt mitochondrial translocation, and enhance the 
levels of proteins involved in mitochondrial protein import, heighten mitochondrial function, and 
precluding mitochondrial ROS formation and cell death induced by mHtt. 
 
Materials and Methods 
Materials: DMEM culture medium and antibiotics were purchased by GIBCO (Paisley, UK). 
Anti-P(Thr308)Akt (ab38449), Anti-SOD1 (ab16831), anti-Ac(K68)SOD2 (ab137037), anti-
SOD2 (ab13533), anti-GCLc (ab17926), anti-Nrf2 (ab31163), anti-P(Ser40)Nrf2 (ab76026), and 
anti-TBP (ab51841) were from Abcam (Cambridge, UK). LY294002 and antibodies against Akt 
(#9272), Erk1/2 (p44/42 MAPK) (#9102), P(Thr202/Tyr204)Erk1/2 (#4377), dynamin-related 
protein 1 (Drp1) or dynamin 1-like (DNM1L) (#8570), P(Ser616)Drp1 (#3455), and were from 
Cell Signaling Technology (Beverly, MA, USA). Anti-heat shock 60kDa protein 1 (chaperonin) 
(Hsp60) (#611562) was from BD Transduction Laboratories (San Jose, CA, USA). Anti-
hexokinase type II (HKII) (AB3279) was from Chemicon (Merck Millipore, Billerica, MA, 
USA). Antibodies against translocase of outer mitochondrial membrane 20 homolog (yeast) 
(Tom20) (sc-11415) and translocase of outer mitochondrial membrane 40 homolog (yeast) 
(Tom40) (sc-11414) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Hoechst 
33342 nucleic acid stain and antibodies against mitochondrial-encoded cytochrome c oxidase II 
(MT-COII) (A-6404), NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa (NADH-
coenzyme Q reductase) (NDUFS3) (A-21343/459130), and succinate dehydrogenase complex, 
subunit A, flavoprotein (Fp) (SDHA) (A-11142) were from Invitrogen/Molecular Probes (Life 
Technologies Corporation, Carlsbad, CA, USA). Secondary antibodies conjugated to alkaline 
phosphatase (anti-mouse, anti-rabbit, and anti-goat) were purchased from Amersham Biosciences 
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(Buckinghamshire, UK). First Strand cDNA Synthesis Kit (AMV) was obtained from Roche 
(Mannheim, Germany). GoTaq Flexi DNA Polymerase and dNTP Mix were obtained from 
Promega (Madison, WI, USA). 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA), 
dihydroethidium, MitoSOX™ Red, Ac-DEVD-AFC (Caspase-3 Substrate VII, Fluorogenic) and 
tetramethylrhodamine methyl ester (TMRM+) were obtained from Calbiochem (Merck Millipore, 
Billerica, MA, USA). Other reagents, anti--actin and anti--tubulin, insulin from porcine 
pancreas, IGF-1, NEM (N-ethylmaleimide), OPA (ortho-phthaldialdehyde), and U0126 were 
from Sigma Chemical Co. (St Louis, MO, USA).  
 
Cell culture: Striatal cells derived from knock-in mice expressing normal Htt (STHdhQ7/Q7 or 
wild-type cells; clone 2aA5) or homozygous to mHtt with 111 glutamines (STHdhQ111/Q111 or
mutant cells; clone 109-1A) were used. Striatal cells were kindly donated by Dr. Marcy E. 
MacDonald (Department of Neurology, Massachusetts General Hospital, Boston, USA). The 
cells were maintained as described previously [38]. Striatal cells were plated on poly-L-lysine 
coated glass coverslips, multiwell chambers or flasks 48 h before the experiments in order to 
allow the desired confluence. In some experiments, cells were pre-incubated for 30 min with 25 
μM LY294002 or 10 μM U0126 before supplementing with insulin or incubating with IGF-1 
(0.1-10 nM) for 24 h. In some experiments, cells were incubated with 500 μM H2O2 during 3 h. 
Intracellular ROS measurements: After brief washing with PBS, striatal cells were incubated 
for 30 min with 20 μM H2DCFDA, at 33ºC, in Krebs medium (in mM: 135 NaCl, 5 KCl, 0.4 
KH2PO4, 1.8 CaCl2, 1 MgSO4, 20 HEPES and 5.5 glucose) at pH 7.4. H2DCFDA is incorporated 
by the cells and hydrolysed by esterases to form H2DCF, which is then converted to DCF by 
intracellular ROS [39]. Intracellular ROS were measured by following DCF fluorescence (488 
nm excitation, 530 nm emission) at 33ºC, continuously, for 1 h, using a Microplate 
Spectrofluorometer Gemini EM (Molecular Devices, USA). Superoxide anion (O2-) formation 
was determined by using the fluorescence probe dihydroehidium (DHE) (Molecular Probes, 
Invitrogen). DHE is permeable to cell membrane and in cytoplasm it is converted to ethidium by 
O2-. Then, ethidium binds to DNA and emits fluorescence [40]. Briefly, 5 μM DHE dissolved in 
Krebs medium was incubated in cells during 1 h at 33ºC. Fluorescence measurements were taken 
during 1 h (518 nm excitation; 605 nm emission) in the presence or absence of 10 μM rotenone, a 
7 
 
mitochondrial complex I inhibitor, or antimycin A, a mitochondrial complex III inhibitor. 
Mitochondrial O2- production levels were measured by using the fluorescent probe MitoSOXTM 
Red. Briefly, striatal cells were washed in PBS, and then incubated with 2.5 μM MitoSOXTM Red 
in Krebs medium during 10 min, at 33ºC. The fluorescence was taken during 1 h and 30 min at 
33ºC with 510 nm excitation and 580 nm emission. In order to correct the DCF, DHE and 
MitoSOXTM Red fluorescence values for variations in total protein content in the wells, cell 
protein in each well was quantified by the BioRad protein assay. The values were obtained as 
RFU (Relative Fluorescence Units) per minute per mg protein for each condition and then 
expressed as a percentage of wild-type cells. 
Nuclear morphometric analysis: Cells were washed in Krebs medium and further incubated 
with Hoechst 33342 (4 μg/mL, a blue permeable fluorescent dye, which binds to DNA, to 
determine nuclear morphology) during 20 min, in the dark. Live cells were analyzed by 
fluorescence microscopy. Images from three different fields for each condition, in a total of four 
different experiments (run in duplicates) were acquired in a fluorescence microscope Axiovert 
200M equipped with a LD Plan-Neofluar/40x/0.6 and an MRm Axiocam (Carl Zeiss, Jena, 
Germany). Images were acquired with Axiovision software and nuclei were counted using an 
ImageJ 1.47v (Wayne Rasband, National Institutes of Health, USA) plugin, which allowed the 
quantification of apoptotic and senescent nuclei accordingly to Filippi-Chiela and collaborators 
[41].  
 
Measurement of SOD activity: Determination of SOD activity was performed accordingly to 
the SOD Assay Kit (Sigma). In order to measure SOD2 activity, 2 mM potassium cyanide (which 
inhibits SOD1) was added.  
Caspase-3 activity: Caspase-3-like activity was determined using a fluorimetric substrate Ac-
DEVD-AFC. Striatal cells were washed 2 times with PBS and then lysed at 4ºC with a buffer 
composed by (in mM): 25 HEPES, 2 MgCl2, 1 EDTA, 1 EGTA, 2 DTT, 0.1 PMSF, and 1:1000 
protease inhibitors and 0.04% Triton X-100 (pH 7.5). After scraping, a reaction buffer composed 
by (final concentrations in the well) 25 mM HEPES, 10% sucrose, 0.1% CHAPS, 2 mM DTT 
and 15 μM Ac-DEVD-AFC (pH 7.5), was added to the cell samples. The fluorescence was taken 
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during 1 h at 33ºC with 400 nm excitation and 505 nm emission. After the readings, cell samples 
were used to determine protein content by Bio-Rad protein assay. The values were obtained as 
RFU (Relative Fluorescence Units) per minute per mg protein for each condition and then 
expressed as a percentage of wild-type cells. 
Measurement of glutathione levels by fluorimetry: The levels of reduced and oxidized 
glutathione (GSH and GSSG, respectively) were measured as described in [17]. Briefly, striatal 
cells were cultured during 48h at 33ºC. After incubation, the cells were washed twice in PBS and 
lysed in 15 mM Tris, pH 7.4, with 0.2% Triton X-100. GSH levels were measured in samples 
after the addition of OPA (1 mg OPA/ml methanol) and 100 mM NaH2PO4. After 15 min 
incubation, the fluorescence was measured using an excitation wavelength of 350 nm and an 
emission wavelength of 420 nm. The experimental procedure for GSSG was similar, although the 
samples were mixed for 30 min with NEM (5 mg NEM/ml methanol) which forms adducts with 
GSH. Then, the mixture was incubated for 15 min in 100 mM NaOH plus OPA (1 mg OPA/ml 
methanol), and the fluorescence was measured with excitation at 350 nm and emission at 420 nm 
in a Gemini EM microplate spectrofluorometer (Molecular Devices, USA). The results were 
calculated as RFU per milligram protein and expressed as percentage of wild-type control cells. 
 
Subcellular fractionation: Cellular and nuclear-enriched fractions were obtained from cells 
that were washed twice in ice-cold PBS and scrapped in lysis buffer 1 (in mM: 10 HEPES, 10 
NaCl, 3 MgCl2, 1 EGTA, 1% Triton X-100, pH 7.5) supplemented with 50 mM NaF, 1.5 mM 
Na3VO4, 1 mM DTT, 1 mM PMSF and 1 g/mL protease inhibitor cocktail (chymostatin, 
pepstatin A, leupeptin and antipain). The cellular homogenate was incubated at 4ºC (on ice) for 
40 min and then centrifuged at 4,700 rpm, for 12 min (4ºC). The pellet was resuspended in buffer 
2 (in mM: 25 HEPES, 300 NaCl, 5 MgCl2, 1 EGTA, 20% glycerol, pH 7.4) supplemented with 
50 mM NaF, 1.5 mM Na3VO4, 1 mM DTT, 1 mM PMSF and 1 g/mL protease inhibitor 
cocktail, incubated on ice for 60 min, and further centrifuged at 10,600 rpm for 20 min (4°C). 
The resulting supernatant was collected and combined with the supernatant obtained from the 
first centrifugation (cellular fraction), whereas the resulting pellet (nuclear-enriched fraction) was 
resuspended in buffer 2. The samples were then frozen and thawed three times in liquid nitrogen, 
sonicated for 30 sec, and the samples were stored at 80 °C.
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To obtain the cytosolic and mitochondrial-enriched fractions, striatal cells were washed with 
PBS and lysed at 4ºC using a sucrose buffer (pH 7.5) composed by (in mM): 250 sucrose, 20 
HEPES, 100 KCl, 1.5 MgCl2, 1 EDTA and 1 EGTA, 1 DTT, 1 PMSF, and 1 g/mL protease 
inhibitor cocktail, homogenized by using a potter (120 strokes). The extracts were centrifuged at 
800 g during 10 min in order to remove nuclear debris. The resulting supernatant was further 
centrifuged at 11,000 g for 10 min. Both the supernatant and pellet were collected into different 
centrifuge tubes. The supernatant was precipitated with acetone 100% and centrifuged at 12,000 
g for 5 min. The resulting supernatant was discarded and the pellet was resuspended in sucrose 
buffer supplemented with 0.5% Triton X-100 (cytosolic fraction). The pellet obtained from the 
second centrifugation was resuspended in sucrose buffer and centrifuged at 11,000 g for 10 min. 
The resulting supernatant was discarded and the pellet was resuspended in sucrose buffer 
supplemented with Triton X-100 and further sonicated for 30 sec (mitochondrial fraction).  
Western Blotting: Samples were denaturated in 50 mM Tris-HCl, pH 6.8, 2% sodium dodecyl 
sulphate (SDS), 5% glycerol, 0.01% bromophenol blue and 100 mM DTT at 95ºC, for 5 min. 
Equivalent amounts of 20-60 g of protein were separated on 7.5%, 10% or 12% SDS-PAGE and 
electroblotted onto polyvinylidene difluoride (PVDF) membranes. The membranes were further 
blocked with 5% BSA and incubated with anti-GCLc (1:1000), anti-SOD1 (1:1000), anti-
Ac(Lys68)SOD2 (1:1000), anti-SOD2 (1:1000), anti-Akt (1:1000), anti-p-(Thr308)Akt (1:500), 
anti-Erk (1:1000), anti-p-(Thr202/Tyr204)Erk (1:500), anti-Nrf2 (1:1000), anti-p-(Ser40)Nrf2 
(1:500), anti-Hsp60 (1:1000), anti-HKII (1:1000), anti-Tfam (1:200), anti-Tom20 (1:200), anti-
Tom40 (1:200), anti-NDUSF3 (1:1000), anti-MT-COII (1:1000), anti-HSP60 (1:1000), anti-Drp1 
(1:1000), anti-p-(Ser616)Drp1 (1:500). Anti--actin (1:5000) was used as loading controls for 
total cellular and cytosolic fractions, while anti-TBP (TATA binding protein) (1:1000) and anti-
SDHA (1:1000) were used as loading controls of nuclear and mitochondrial fractions, 
respectively. Immunoreactive bands were visualized by alkaline phosphatase activity after 
incubation with ECF reagent, by using a BioRad Versa Doc 3000 Imaging System. For 
membrane reprobing, a mild stripping buffer was used, consisting of 1.5% glycine, 0.1% SDS, 
1% Tween20, with pH adjusted to 2.2. Band intensities were quantified and corrected for 
background using Image Studio Lite Software (LI-COR Biosciences, Lincoln, Nebraska, USA). 
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Luciferase gene reporter assay: Nrf2 transcription activity was measured based on its 
capability of binding the antioxidant responsive element (ARE), promoting luciferase gene 
transcription. Striatal cells plated on 12-well plates (90,000 cells/well) were transfected with the 
reporter construct [pGL4.37[luc2P/ARE/Hygro] (Promega) using Fugene 6 (Promega) by adding 
1.1 μg plasmid. After 24 h, cells were exposed to insulin (0.1 nM) for another 24 h. 3 days after 
transfection, cells were washed with PBS and incubated at -80ºC for 2 h in Lysis Buffer (1.15 M 
Tris, 1 mM EDTA, 8 mM MgCl2, 15% glycerol, 1 mM DTT, 1% Triton X-100, pH 7.4). Cells 
were then scraped and samples were centrifuged (5 min, 4ºC at 14,000 rpm). 50 μl of the 
supernatant were transferred to a white opaque 96-wells plate. The luciferase activity was 
measured in a Microplate Luminometer Reader LMax 384 (Molecular Devices, USA) using two 
different buffers: Reading Buffer (1.15 M Tris, 1 mM EDTA, 8 mM MgCl2, 15% glycerol, 1 mM 
DTT, 2 mM ATP, pH 7.4) and Luciferase Buffer (167 μM; prepared in water with pH 8). In order 
to correct the luciferase activity, the protein content in each well was measured by the Bio-Rad 
protein assay (Bradford method). The percentage of luciferase activity was then normalized to 
controls (wild-type cells transfected without any treatment). 
Total RNA extraction, cDNA conversion and RT-PCR: RNA from different samples was 
obtained with Trizol Reagent according to the manufacturer’s protocol. Briefly, striatal cells were 
lysed with Trizol and were homogeneized with a pipette. The RNA was precipitated with 
isopropyl alcohol and the final pellet was resuspended with water DEPC (diethylpyrocarbonate) 
0.01% (v/v). Before performing RT-PCR, the quality of RNA was verified through an 
electrophoresis in 1% agarose gel to check the ribosomal RNA subunits 18S and 28S. Then, the 
samples were incubated at 65ºC for 15 min, to avoid extensive secondary structure that may 
interfere with the annealing step and then were chilled on ice for 5 min. The concentration of 
RNA was measured and 1 g was used to transcribe RNA into cDNA with First Strand cDNA 
Synthesis Kit (AMV). The reaction was as follow: 10 min at +25°C and 60 min at +42°C, for 
primer annealing and cDNA synthesis, respectively, 5 min at +99°C, for the denaturation of 
reverse transcriptase and then the samples were cooled to +4°C for 5 min. 
Quantification of GCLc, HO-1 and NQO1 mRNA levels: The cDNA of each sample (10 ng) 
was amplified using sequence-specific primers to GCLc: forward (5’-3’) ATG GGG CTG CTG 
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TCC CAA G; reverse (5’-3’) GTA TGA GAG GAT CAC CCT AG; HO-1: forward (5’-3’) GCT 
CAC GGT CTC CAG TCG CC; reverse (5’-3’) CAC TGC CAC TGT TGC CAA C; NQO1: 
forward (5’-3’) AGG CTC AGC TCT TAC TAG C; reverse (5’-3’) ATT CAT TTT GTT GTT 
ATG GCA G. The normalization of the amplified product was performed in relation to the 
product of actin obtained in the same samples using as primers (5’-3’) GGA GAC GGG GTC 
ACC CAC AC and (5’-3’) AGC CTC AGG GCA TCG GAA CC, forward and reverse 
respectively. All reactions were performed using GoTaq Flexi DNA Polymerase (5x kit) and 10 
mM dNTP Mix. The amplification reaction mixture (50 l) contained 10 l of the cDNA 
template, 1.5 mM of MgCl2, 0.2 M of each primer, 0.05 U Taq Pol. The thermal cycling 
conditions included 3 min at 94ºC, proceeding with 40 cycles of 94ºC for 30 s, 57ºC for 30 s and 
72ºC for 45 s, followed by 72ºC for 10 min. The size of the PCR products was visualized in a 
1.7% agarose gel and analyzed afterwards. GCLc, HO-1 or NQO1 mRNA levels were expressed 
in relation to actin. 
Analysis of mitochondrial membrane potential: Mitochondrial membrane potential was 
determined using the cationic fluorescent probe TMRM+, widely used as a fluorescent probe for 
measuring in situ mitochondrial membrane potential [42]. The experiments were performed 
accordingly to [43], with minor modifications. Briefly, cells were cultured in a 96-well plate 
during 48 h, at 33ºC. Then, striatal cells were washed twice in PBS and 300 nM TMRM+ (diluted 
in Krebs medium) was incubated during 1 h, at 33ºC. After incubation, the basal fluorescence 
was taken during 5 min using a Microplate Spectrofluorometer Gemini EM (Molecular Devices, 
USA) (540 nm excitation and 590 emission). FCCP (2.5 M) and oligomycin (2 g/ml), which 
produced maximal mitochondrial depolarization, were added to cells and the fluorescence was 
taken during another 5 min. Results were expressed as the difference between the increase in 
TMRM+ fluorescence upon addition of FCCP plus oligomycin and basal fluorescence values, and 
converted to percentage of wild-type (control) cells.
Statistical analysis: Statistical significance was determined by one-way or two-way ANOVA 
followed by the Bonferroni post-hoc test for multiple groups or by the Student’s t-test for 
comparison between two Gaussian populations, as described in figure legends. Data were 
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expressed as the mean ± S.E.M. of the number of experiments indicated in figure legends. 
Significance was accepted at p<0.05.
 
Results 
Insulin and IGF-1 prevent increased mitochondrial-driven ROS generation and apoptotic 
features in HD mutant striatal cells 
Initially we determined the effect of insulin and IGF-1 on ROS formation in STHdhQ111/Q111 
cells. Due to structural and functional homology, insulin and IGF-1 can bind to (and activate) 
both insulin receptor (IR) and insulin-like growth factor 1 receptor (IGF1R), with insulin binding 
to the IR with higher affinity (< 1 nM) than IGF-1 (100–500-fold lower affinity), whereas IGF1R 
preferentially binds IGF-1 (< 1nM) as compared to insulin (100–500-fold lower affinity) [44]. 
Taking this into account, striatal cells were exposed to insulin or IGF-1 in the low nM range (0.1-
10 nM).  
Mitochondrial O2- was measured using MitoSOX Red, a triphenylphosphonium cation 
conjugated with hydroethidine that readily reacts with O2•- [45], although it may also non-
specifically oxidize [46]. Importantly, a significant increase in mitochondrial O2•- (Fig. 1A) was 
observed in HD knock-in striatal cells expressing full-length mHtt (STHdhQ111/Q111 or mutant 
cells), when compared to STHdhQ7/Q7 cells (wild-type cells). Enhanced levels of mitochondrial-
generated O2•- in mutant cells were further revealed with the fluorescent probe hydroethidine 
following exposure to rotenone (complex I inhibitor) and antimycin A (complex III inhibitor) 
(Fig. 1B), thereby confirming increased production of mitochondrial ROS. When exposed to 
insulin or IGF-1, mutant cells presented a significant decrease in mitochondrial O2- formation 
(Fig. 1A). Moreover, both insulin and IGF-1 significantly precluded the generation of other ROS 
in mutant cells (supplementary Fig. S1A,B), as assessed with the fluorescent redox probe 
H2DCFDA, which can be oxidized by hydroperoxides, peroxynitrite (ONOO-), hydroxyl radicals 
(OH) or hypochlorous acid, among other oxidants, and redox-active metals such as iron [46]. 
These data show that both insulin and IGF-1 (at low nM) preclude mHtt-induced generation of 
ROS, in particular mitochondrial O2-. 
Because caspase-3 activation was previously observed in HD striatal cells [17,47,48], 
correlating with nuclear apoptotic features [49], we determined the effect of insulin and IGF-1 on 
caspase-3 activation and nuclear morphology, namely apoptotic and senescent nuclei, in mutant 
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versus wild-type cells. Insulin (0.1 nM) significantly protected against caspase-3 activation in 
mutant cells (Fig. 2A), whereas both insulin and IGF-1 (0.1 nM) largely reduced apoptotic and 
senescent nuclei induced by expression of mHtt (Fig. 2C). Notably, no changes in caspase-3 
activity or apoptotic and senescent nuclei were observed in wild-type cells treated with insulin or 
IGF-1 (Fig. 2A,B). 
 
Full-length mHtt modifies SOD1/2, GCL catalytic and glutathione levels – influence of 
insulin and IGF-1 
In order to examine whether elevated levels of ROS in mutant cells, namely O2-, were due to 
alterations in antioxidant activities, we determined SOD1/2 activities and protein levels. A 
significant increase in SOD2 activity was observed in total cell extracts from mutant, compared 
to wild-type cells (Fig. 3A), suggesting a compensatory mechanism against high levels of 
mitochondrial O2•-. Concordantly, SOD2 activity was increased in mitochondrial fractions from 
mutant cells (Fig. 3B). Since acetylation of SOD2 at Lys68 was reported to decrease its activity 
[50], we measured the acetylation levels of SOD2 in striatal cells. In agreement with increased 
SOD2 activity, we detected a decrease in Ac-SOD2/SOD2 ratio in mutant cells (Fig. 3C). 
Interestingly, a decrease in SOD2 protein levels was also verified in mutant cells (Fig. 3D). 
Exposure to insulin induced a significant increase in SOD2 acetylation levels in mutant cells (Fig. 
3C), whereas IGF-1 increased SOD2 protein levels (Fig. 3D) without changing protein 
acetylation in mutant cells (Fig. 3C). We also observed increased activity of SOD1 in total (Fig. 
3E) and mitochondrial (Fig. 3F) fractions; however no differences in SOD1 protein levels were 
detected in mutant versus wild-type cells (Fig. 3G). Moreover, both insulin and IGF-1 
significantly decreased mitochondrial SOD (1 and 2) activities in mutant cells (Fig. 3H). These 
results indicate that increased ROS caused by expression of full-length mHtt largely correlate 
with increased SOD1 and 2 activities and that treatment with insulin or IGF-1 precluded the 
increase in SOD activity. 
We previously showed that the activity of enzymes of the glutathione redox cycle were 
enhanced, whereas GCL and glutathione synthetase (GS) activities and protein levels of GCLc 
were decreased in HD mutant striatal cells [17]. Therefore, we determined the effect of insulin 
and IGF-1 on GCLc protein levels. GCLc levels were significant decrease in mutant cells, when 
compared to wild-type cells (Fig. 4A,B). Treatment with 0.1 nM insulin increased GCLc levels in 
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mutant cells, whereas IGF-1 (0.1 and 1 nM) increased GCLc levels in wild-type cells only, 
compared to non-treated conditions (Fig. 4A,B). A rise in glutathione levels in mutant cells, 
despite decreased GCL activity, was previously demonstrated [17]. Therefore, we tested whether 
insulin or IGF-1 could alter GSH and GSSG levels. Insulin slightly increased GSH and GSSG in 
wild-type cells, however, neither insulin nor IGF-1 altered GSH or GSSG levels in mutant cells 
(Fig. 4C,D). These data indicate that insulin ameliorates GCLc protein levels, although not 
affecting GSH or GSSG levels in cells expressing mHtt. 
 
Insulin and IGF-1 enhance phosphorylated Nrf2 nuclear levels, but do not affect its 
transcriptional activity in HD striatal cells 
In order to evaluate whether antioxidant response was induced by insulin and/or IGF-1, we 
analysed the levels of the transcription factor Nrf2, which is responsible for the transcription of 
many antioxidant enzymes, including SOD1 and GCLc, and thus is directly implicated in cellular 
detoxifying systems [32,51]. Human Nrf2 contains 605 amino acids with a predicted relative 
molecular mass (Mr) of 66 kDa (57 kDa in mice). However, it was shown that transcription and 
translation of the full-length Nrf2 cDNA produces a band at 66 kDa and a higher Mr band at 
approximately 96 kDa, likely due to the abundance of acidic residues in Nrf2 [52]. Lau and 
collaborators [53] have recently reported that the biologically relevant Mr of Nrf2 ranges from 
~95-110 kDa. Indeed, we detected a strong band around 100 kDa for phosphorylated p-(Ser40)-
Nrf2 in both cellular and nuclear fractions obtained from striatal cells. However, in the case of 
Nrf2 two bands of ~57 kDa and ~90 kDa were detected in cellular fractions, whereas a single 
band of ~90 kDa appeared in the nuclear fraction. In the present study we quantified the ~100 
kDa band for p-(Ser40)-Nrf2 and the ~90 kDa band for Nrf2.  
Protein kinase C phosphorylates Nrf2 at Ser40, leading to Nrf2 dissociation from its 
endogenous inhibitor Kelch-like ECH associated protein 1 (Keap1), which results in nuclear 
translocation of Nrf2 in response to oxidative stress [54]. Therefore, we measured the levels of p-
(Ser40)-Nrf2/Nrf2 in both cellular and nuclear extracts of striatal cells. Phosphorylated p-
(Ser40)-Nrf2/Nrf2 ratio in cellular fractions did not differ significantly between both cell types 
(wild-type and mutant) (Fig. 5A,B). In nuclear-enriched fractions derived from mutant cells, p-
Nrf2/Nrf2 ratio was increased (Fig. 5C,D) when compared to wild-type cells; however, this did 
not correlate with Nrf2/ARE transcriptional activity, which was significantly decreased in HD 
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cells (Fig. 5E). The oxidant H2O2, used as a positive control to induce the oxidation of Keap1 
cysteine residues and Nrf2 dissociation from Keap1 [55], increased both cellular and nuclear p-
Nrf2/Nrf2 ratio levels in both striatal cells, although it only reached statistical significance in 
nuclear fractions from wild-type cells (Fig. 5A-D). Incubation of wild-type cells with 0.1 nM 
insulin or IGF-1 significantly increased nuclear p-Nrf2/Nrf2 ratio (Fig. 5C,D) and insulin 
enhanced Nrf2/ARE activity (Fig. 5E). However, exposure to insulin or IGF-1 did not alter p-
Nrf2/Nrf2 in cellular or nuclear fractions, or Nrf2/ARE transcriptional activity in mutant cells 
(Fig. 5A-E).  
In the nucleus Nrf2 activates the transcription of genes involved in antioxidant defense, 
including GCLc, NAD(P)H dehydrogenase [quinone] 1 (NQO1), heme oxygenase (HO-1), 
among others [51]. In order to examine the importance of Nrf2 in regulating the oxidant status in 
mutant cells and since we detected increased GCLc protein levels following insulin treatment, we 
determined the levels of mRNA of GCLc, NQO1 and HO-1 under basal conditions and after 
exposure to insulin and IGF-1 (Supplementary Fig. S2). In agreement with the decrease in 
Nrf2/ARE transcriptional activity and GCLc protein levels in untreated mutant cells, we observed 
a significant reduction in GCLc mRNA levels in HD knock-in cells, when compared to wild-type 
cells (Fig. S2A). No significant changes in GCLc mRNA levels were observed after treatment 
with 0.1 nM insulin or IGF-1 (Fig. S2B), concordantly with insulin inefficiency in promoting 
Nrf2 transcriptional activity (Fig. 5E). NQO1 and HO-1 mRNA were not significantly altered in 
untreated mutant versus wild-type cells, or after exposure to insulin or IGF-1 either (Fig. S2C-F).  
Data suggest that mHtt-induced increased ROS is linked to increased nuclear Nrf2 
phosphorylation, but reduced Nrf2-dependent transcriptional activity of antioxidant defense 
systems, which may further enhance the cellular levels of ROS (Fig. 1, S1). Although insulin and 
IGF-1 induced nuclear translocation of p-Nrf2 and transcriptional activation in wild-type cells, in 
the presence of mHtt Nrf2 activity was not stimulated by insulin or IGF-1 treatments, indicating 
that insulin- and IGF-1-induced protection against ROS formation in HD striatal cells is 
independent of Nrf2-regulated antioxidant response. 
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Insulin and IGF-1 ameliorate mitochondrial membrane potential via the PI-3K/Akt pathway 
in mutant cells 
Because insulin and IGF-1 are able to stimulate intracellular signaling pathways, we next 
investigated the role of PI-3K/Akt and Erk in regulating an upstream pathway of cell survival 
linked to increased mitochondrial function. We measured total and phosphorylated levels of Akt, 
and Erk42/44 in wild-type and HD striatal cells, in the absence or presence of 0.1 nM insulin or 
IGF-1 (Fig. 6).  
Expression of mHtt per se significantly decreased the ratio of cytosolic phosphorylated p-
(Thr308)Akt/total Akt, and total Akt/actin, without changing cellular p-
(Thr202/Tyr204)Erk(42/44)/total Erk(42/44) or total Erk(42/44) levels (Fig. 6A-F), indicating 
decreased activation of phosphatidylinositol 3-kinase (PI-3K)/Akt signaling pathway. We 
analysed p-(Thr308)Akt, which is phosphorylated by phosphoinositide-dependent protein kinase 
1 (PDPK1), since it was described to better correlate with Akt protein kinase activity [56]. 
Exposure to 0.1 nM insulin or IGF-1 significantly increased p-(Thr308)Akt/total Akt (Fig. 6A,C), 
whereas both stimuli significantly decreased total Akt/actin (Fig. 6B,C) in both striatal cells, and 
decreased cellular p-(Thr202/Tyr204)Erk(42/44)/total Erk(42/44) ratio in mutant cells (Fig. 
6D,F). No changes were verified in total Erk(42/44) levels with either insulin or IGF-1 stimuli in 
both striatal cells (Fig. 6E,F). Because Akt can activate mammalian target of rapamycin (mTOR) 
[57], we also analyzed the levels of p-(Ser2448)mTOR/mTOR; however, no significant effects 
were observed in the presence of insulin or IGF-1 in both striatal cells (data not shown). These 
results suggest that insulin and IGF-1 may regulate pro-survival responses in mutant striatal cells 
by activating Akt.  
Akt also phosphorylates cAMP response-element (CRE) binding protein (CREB), promoting 
CBP recruitment to initiate gene transcription [58]. HD has been linked to dysregulation of 
CREB/CRE transcription leading to decreased activity of PGC-1 (peroxisome proliferator-
activated receptor- co-activator 1), a transcriptional regulator of mitochondrial biogenesis and 
antioxidant enzymes [59]. mHtt also interacts with and sequesters CBP within protein aggregates 
[60,61]. Analysis of CBP and PGC-1 in nuclear-enriched fractions from wild-type and mutant 
striatal cells revealed no significant differences after treatment with 0.1 nM insulin or IGF-1 (data 
not shown), indicating that CBP and PGC-1 are not affected by insulin or IGF-1. 
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Taking into account that insulin and IGF-1 protected from mitochondrial O2- generation 
induced by expression of mHtt (Fig. 1), we next tested whether insulin and IGF-1 influenced 
mitochondrial fragmentation and function.  
mHtt was previously described to bind Drp1, increasing its activity [62,63]. Drp1 is a 
cytosolic protein that translocates to the outer mitochondrial membrane to promote mitochondrial 
fragmentation. Phosphorylation of Drp1 at Ser616 is a target of several kinases, including Erk1/2, 
and was shown to enhance Drp1 activity, resulting in mitochondrial fragmentation [64]. In order 
to verify if Drp1 is actively increased in mutant cells, we measured the levels of p-(Ser616)Drp1 
and total Drp1 in mitochondrial fractions. We observed increased p-(Ser616)Drp1/Drp1 in the 
mitochondria of mutant cells, compared to wild-type cells (Fig. 7A,C), despite decreased levels 
of Drp1 (Fig. 7B,C), suggesting increased mitochondrial fragmentation upon expression of mHtt. 
Treatment with insulin or IGF-1 significantly decreased mitochondrial p-(Ser616)Drp1/Drp1 in 
mutant cells (Fig. 7A,C), without affecting Drp1 levels (Fig. 7B,C). These data suggest that 
insulin and IGF-1 decrease mHtt-induced mitochondrial fragmentation. 
Mitochondrial membrane potential, measured with TMRM+ after complete depolarization 
with FCCP plus oligomycin, was decreased by almost 50% in mutant cells (Fig. 7D), revealing 
increased mitochondrial depolarization induced by mHtt. Both insulin and IGF-1 (0.1 nM) 
significantly increased mitochondrial membrane potential in mutant cells (Fig. 7D). Considering 
that SODs dismutate mitochondrial O2- into H2O2, we verified whether increased ROS levels 
affected mitochondrial membrane potential in mutant striatal cells by analyzing the effect of 
exposure to H2O2 (500 μM, for 3 h). H2O2 greatly induced mitochondrial depolarization in both 
striatal cells (Fig. 7E). These data show that insulin and IGF-1 improve mitochondrial function, 
which appears to be in accordance with the decrease in mitochondrial ROS formation observed in 
HD striatal cells. 
Because insulin and IGF-1 induced Akt activation and significantly decreased mitochondrial 
depolarization, compared to untreated mutant cells, we further tested whether the PI-3K/Akt 
pathway was involved in improving mitochondrial function in mutant cells, by testing the effect 
of LY294002, a highly selective inhibitor of PI-3K [65]. LY294002 (25 μM) decreased p-
(Thr308)Akt/total Akt and thus Akt activation, as determined by western blotting (data not 
shown). No significant changes in mitochondrial membrane potential were observed in both 
striatal cells after treatment with LY294002 (Fig. 7F,G). However, insulin and IGF-1-evoked 
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increase in mitochondrial membrane potential was completely abrogated by LY294002 in mutant 
cells (Fig. 7G), whereas no changes were observed in wild-type cells (Fig. 7F). Thus, insulin and 
IGF-1 largely improve mitochondrial function through the PI-3K/Akt pathway in HD mutant 
cells. 
In order to verify if insulin and IGF-1-induced increased mitochondrial membrane potential 
was dependent on Erk(42/44) activation, we tested the effect of U0126, an inhibitor of MEK/Erk 
activity [66]. U0126 (10 μM) decreased p-(Thr202/Tyr204)Erk(42/44)/total Erk(42/44) and thus 
Erk activation, as determined by western blotting (data not shown). U0126 per se caused a 
significant increase in mitochondrial membrane potential in both wild-type and mutant striatal 
cells (Fig. 7H,I); moreover, incubation with U0126 enhanced mitochondrial membrane potential 
in IGF-1-treated mutant cells (Fig. 7I).  
 
Insulin and IGF-1 modify the levels of several proteins in mitochondria derived from mutant 
striatal cells 
In order to further investigate PI-3K/Akt-dependent improvement in mitochondrial function 
evoked by insulin and IGF-1 in HD striatal cells (Fig. 7G), we next measured p-(Thr308)Akt and 
Akt levels in mitochondrial fractions of striatal cells. We used succinate dehydrogenase complex, 
subunit A, flavoprotein (Fp) (SDHA) protein for western blotting normalization, since it was the 
less variable protein found in mitochondrial fractions. Under basal/unstimulated conditions 
mitochondrial p-Akt(Thr308) levels were slightly decreased in mutant cells (Fig. 8A,L). 
Treatment with insulin or IGF-1 increased p-(Thr308)Akt and total Akt levels in mitochondria 
derived from mutant cells, whereas in wild-type cells only IGF-1 had a similar effect (Fig. 
8A,B,L). Enhanced Akt protein levels in mitochondria (Fig. 8B) appear to correlate with 
decreased cytosolic Akt (Fig. 6B) after treatment with insulin or IGF-1.  
Since the inhibitor of MEK/Erk signaling showed increased mitochondrial membrane 
potential in both striatal cells (Fig. 7H,I), we also analysed the levels of mitochondrial p-
(Thr202/Tyr204)Erk(42/44) and total Erk(42/44). We verified a dramatic increase in the levels of 
mitochondrial p-(Thr202/Tyr204)Erk(42/44) in mutant cells compared to wild-type cells (Fig. 
8C,L), but no changes observed for total Erk(42/44) levels (Fig. 8D,L). Neither insulin nor IGF-1 
were able to reduce Erk(42/44) activation in mitochondria of mutant cells, while IGF-1 only 
decreased Erk(42/44) activation in wild-type cells (Fig. 8C,L).  
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Akt was described to phosphorylate hexokinase II (HKII) at Thr473, increasing HKII 
association with mitochondria and resulting in protection against H2O2 treatment [67]. Following 
treatment with insulin and IGF-1, mitochondrial HKII levels increased in both striatal cells, 
however it only reached significance in the case of IGF-1 (Fig. 8E,L). Heat shock 60kDa protein 
1 (chaperonin) (Hsp60) was shown to directly interact with Akt1 resulting in its activation [68]. 
Mutant cells displayed significant reduced mitochondrial Hsp60, when compared to wild-type 
cells, while treatment with IGF-1, in particular, promoted increased Hsp60 levels in both striatal 
cells (Fig. 8F,L).  
Because insertion of nuclear-encoded proteins in mitochondria largely depends on the 
presence of Tom20 (translocase of outer mitochondrial membrane 20) or Tom40 (translocase of 
outer mitochondrial membrane 40), among other translocases, we determined their protein levels 
in mitochondrial fractions derived from striatal cells. Tom20 was significantly decreased in 
mutant cells (Fig. 8G,L), suggesting deficits in the recognition and movement of cytosolically 
synthesized mitochondrial preproteins; importantly, this difference was alleviated after 
incubation with insulin and IGF-1 (Fig. 8G,L). Both peptides also enhanced mitochondrial 
Tom40 levels in wild-type cells (Fig. 8H,L), whereas insulin only increased Tom40 levels in 
mitochondria of mutant cells (Fig. 8H,L). These data suggest that insulin might induce increased 
mitochondrial import of preproteins.  
Finally, we determined the influence of insulin and IGF-1 on mitochondrial levels of 
mitochondrial transcription factor A (Tfam), involved in mtDNA transcription and replication, in 
mitochondria derived from mutant and wild-type striatal cells. In previous studies the exogenous 
oxidant t-butyl hydroperoxide (t-BOOH) induced Akt activation, which in turn directly 
phosphorylated nuclear respiratory factor 1 (NRF-1) leading to its nuclear translocation and 
binding to Tfam promoter, resulting in its transcription [69]. Tfam levels were significantly 
decreased in mitochondria of mutant cells (Fig. 8I,L). In HD cells, insulin slightly increased, 
while IGF-1 greatly enhanced mitochondrial Tfam levels (Fig. 8I,L). To check whether increased 
Tfam in mitochondria correlated with modified mitochondrial DNA-encoded proteins, we 
analysed the protein levels of NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa 
(NADH-coenzyme Q reductase) (NDUSF3), a nuclear-encoded complex I subunit, and 
cytochrome c oxidase II (MT-COII), a mitochondrial-encoded complex IV subunit, in 
mitochondrial fractions derived from striatal cells. Under basal conditions there were no 
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differences in NDUSF3 or MT-COII protein levels (Fig. 8J,K,L). No changes in NDUSF3 were 
detected in mutant cells after treatment with insulin or IGF-1 (Fig. 8J,L) either. Conversely, 
treatment with insulin or IGF-1 promoted a significant increase in MT-COII protein levels 
particularly in mitochondria of mutant cells (Fig. 8K,L).  
These data suggest that insulin and IGF-1 enhance the protein levels of several proteins 
related with increased mitochondrial function in HD cells, which may occur through the 
translocation of cytosolic proteins to the mitochondria and/or possible Akt-mediated 
phosphorylation of target proteins; moreover, increased mitochondrial Tfam levels correlate with 
enhanced levels of mitochondrial-encoded complex IV subunit in mutant cells exposed to insulin 
or IGF-1. 
Discussion 
Here we show that expression of full-length mHtt increases mitochondrial O2- generation and 
impairs Nrf2 transcriptional activity resulting in decreased GCLc mRNA and protein levels. 
Nevertheless, neither insulin nor IGF-1 influence the expression of Nrf2-target genes (GCLc, 
NQO1 and HO-1) in HD striatal cells. Moreover, exposure of HD striatal cells to insulin and 
IGF-1 stimulate PI-3K/Akt pathway, promoting restoration of mitochondrial function, which 
correlate with decreased mitochondrial O2- production and cell death. Importantly, insulin and 
IGF-1 reduce Drp1 activity, suggesting decreased mitochondrial fragmentation. Translocation of 
Akt to mitochondria and increased mitochondrial Akt activity, along with enhanced levels of 
mitochondrial proteins, namely HKII, Hsp60, Tom 20 and Tom40, Tfam and MT-COII, appear to 
mediate the protective effects induced by insulin and IGF-1. 
Increased mitochondrial generation of ROS in HD striatal cells was accompanied by 
increased activities of SOD1/2, which was confirmed by reduced SOD2 acetylation. Treatment 
with insulin and IGF-1 reduced ROS levels and restored the activity of mitochondrial SOD 
activity in mutant cells, indicating diminished antioxidant response. Interestingly, insulin even 
promoted increased SOD2 acetylation, correlating with lower mitochondrial SOD activity, 
whereas IGF-1 increased SOD2 protein levels without changing its acetylation. An increase in 
SOD activity was previously observed in R6/1 HD mice at 19 weeks of age, although older mice 
exhibited decreased SOD activity [70]. Reduced activity of SOD1 was also observed in cortex 
and cerebellum of post-mortem human brain tissues [7] and in erythrocytes [5] of HD patients. In 
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a previous study we demonstrated increased ROS levels and decreased GCL activity, despite 
increased glutathione levels in HD striatal cells, which occurred as a result of a lower capacity of 
multidrug resistance-associated protein 1 (Mrp1) to export GSH to the extracellular space [17]. 
Although we detected increased p-Nrf2/Nrf2 nuclear levels in HD striatal cells, in contrast to van 
Roon-Mom and collaborators [71] we did not observe activation of Nrf2-responsive genes upon 
expression of mHtt under non-stimulated conditions. Indeed, Nrf2/ARE transcriptional activity 
was decreased in HD knock-in striatal cells, which was related with reduced mRNA and protein 
levels of GCLc. While insulin moderately enhanced GCLc protein levels in mutant striatal cells, 
no changes in GCLc expression were observed and glutathione levels remained unchanged, 
largely suggesting that ROS protection induced by insulin or IGF-1 is independent on glutathione 
antioxidant response. Moreover, expression of other Nrf2-target genes, such as HO-1 and NQO1, 
was not affected by insulin or IGF-1 either. Acetylation of Nrf2 by CREB-binding protein (CBP) 
was previously described to increase Nrf2 promoter-specific DNA binding [72]. Therefore, we 
hypothesize that insulin or IGF-1 may not be able to increase Nrf2 acetylation and promote its 
activity and/or may not efficiently bind to ARE due to the presence of mHtt in the nucleus. 
We previously showed that HD striatal cells exhibit features of intrinsic apoptosis [48]. 
Enhanced caspase-3 activation has been linked to increased mitochondrial ROS formation. 
Indeed, we showed that there is a close interplay between endogenous ROS generation and 
caspase-3 activation in apoptotic neurons [43,73]. Both insulin and IGF-1 lowered the number 
apoptotic and senescent nuclei in mutant cells and prevented ROS generation in mutant cells, 
while insulin only was able to prevent caspase-3 activation in cells expressing mHtt. This may 
account for by differential activation of pro-survival signaling pathways in knock-in HD striatal 
cells exposed to insulin or IGF-1. Previously we demonstrated that insulin (at microM 
concentrations, potentially activating both insulin and IGF-1 receptors) can act as an antioxidant 
in cortical neurons, under conditions involving activation of Akt and inhibition of glycogen 
synthase kinase 3 beta (GSK3) [31,74]. Indeed, unstimulated HD knock-in striatal cells showed 
reduced activation of PI-3K/Akt signaling pathway, which was stimulated by IGF-1 and insulin. 
Reduced Akt was previously reported in HD patients, appearing as a shorter inactive caspase-3-
cleaved form [27,75]. Corroborating our study, p-(Ser473)Akt/Akt levels were significant 
decreased in STHdhQ111/Q111 cells [76], in HEK293 cells expressing mHtt with 68 CAG repeats 
[77] and in HD patient’s lymphoblasts and lymphocytes [75]. Akt activation is an early pro-
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survival striatal response in knock-in HdhQ111 mice and STHdhQ111/Q111 cells [28]; importantly, 
activation of IGF-1/Akt pathway caused Htt phosphorylation at Ser421, decreasing mHtt nuclear 
inclusions and mHtt toxicity [27] and regulated anterograde and retrograde transport defects in 
HD cortical neurons [78]. Another study demonstrated that p-(Ser473)Akt was unchanged in 
YAC128 and in R6/2 HD mice, but the levels of p-(Ser421)Htt were decreased in the striatum of 
YAC128 mice and in cells expressing mHtt [79]. In contrast, insulin receptor substrate (IRS)-2, 
which activates PI-3K/Akt and mTOR cascade, promoted mitochondrial dysfunction and 
oxidative stress in R6/2 mice; however, in the same study, the authors showed that IRS-2 protein 
levels were unchanged in the striatum of patients with grade II HD [80]. Conversely, IRS-2 
activation induced by insulin, IGF-1 and interleukin-4 enhanced exon1Htt clearance in a dose-
dependent manner [81]. Thus, different IRS signaling pathways might be activated upon 
exposure to low nM insulin or IGF-1.  
Plasma IGF-1 levels were previously shown to be reduced in HD patients, compared with 
controls [82], but higher IGF-1 in plasma correlated with cognitive decline in HD patients [83]. 
However, in another study, reduced IGF-1 mRNA was observed in striatum and skin fibroblasts 
of HD patients and HD knock-in striatal cells, and decreased plasma IGF-1 levels correlated with 
decreased body weight in R6/2 HD mice [26]. Additionally, we previously described that 
recombinant human IGF-1 (rhIGF-1) rescued peripheral metabolic abnormalities linked to 
diabetes in R6/2 mice [29]. More recently, we showed that intranasal administration of rhIGF-1 
for 2 weeks, in order to promote IGF-1 delivery to the brain, enhanced IGF-1 cortical levels and 
improved motor activity and both peripheral and central metabolic abnormalities in YAC128 
mice [30], an animal model presenting high levels of IGF-1 in plasma and expression in the 
striatum [26]. We also showed that rhIGF-1 intranasal administration in YAC128 mice activated 
Akt and increased mHtt phosphorylation at Ser421, suggesting that activation of IGF-1 signaling 
pathways is linked to amelioration of HD-associated glucose metabolic brain abnormalities and 
mice phenotype [30]. In lymphoblats from HD patients, we recently demonstrated that IGF-1 and 
insulin activate IR and IGF1R, Akt and Erk, and stimulate Htt phosphorylation at Ser421, 
increasing O2 consumption, mitochondrial membrane potential, ATP and phosphocreatine levels, 
and decreasing lactate levels [84]. These data are consistent with stimulation of Akt signaling in 
insulin and IGF-1-treated HD cells. 
23 
 
Conversely to Akt, MEK/Erk1/2 was unchanged and both insulin and IGF-1 reduced Erk 
activation in mutant cells. Erk was previously described to protect against mHtt toxicity [85] and 
decreased p-Erk was found in STHdhQ111/Q111 cells [86]. The difference obtained with the same 
cell model might be explained by the possibility that different STHdhQ111/Q111 cell clones might 
have contrary results in some proteins [e.g. 47]. Previous data showed that IGF-1 may induce an 
early and transient Erk activation but abrogate the appearance of late and sustained Erk by 
activating PI-3K/protein kinase A, which phosphorylate c-Raf at Ser259, leading to Erk 
inhibition [87]. Also, insulin was shown to inhibit Erk1/2 phosphorylation in a PI-3K-dependent 
manner in Neuro2a cells [88]. In R6/2 HD mice, Fusco and collaborators [89] investigated Erk 
activation among different subsets of striatal neurons. They verified that the most susceptible 
striatal neurons to degeneration in HD, striatal medium spiny projection neurons and 
parvalbuminergic interneurons, exhibited increased p-Erk levels with disease progression. 
Conversely, the subsets of neurons that are more resistant to HD degeneration, namely 
somatostatin-NOS-NPY and cholinergic interneurons, showed decreased p-Erk with disease 
progression in the R6/2 mice [89]. This appears to indicate that Erk activity may be directly 
involved in HD progression and can define differences in striatal neuronal susceptibility. 
Mitochondria in HD striatal cells were recently described to be altered and more vulnerable to 
oxidative stress [33,49]. Indeed, elevated mitochondrial O2- generation in HD knock-in striatal 
cells has been linked to mitochondrial dysfunction [90,91]. In HD striatal neurons, ROS 
formation may be a consequence of mitochondrial dysfunction through defects of mitochondrial 
respiratory complexes [47], which occur early in disease progression, as recently shown by us 
[19]. Indeed, the striatum is highly susceptible to dysfunction of mitochondrial oxidative 
phosphorylation [92]. ROS formation in HD can further damage mitochondria by dissipating the 
mitochondrial membrane potential, dysregulating ATP production and leading to oxidation of 
mtDNA [8,23,93], which is highly vulnerable to oxidative damage due to its proximity to the 
respiratory chain, limited repair mechanisms, few non-coding sequences and lack of histones 
[94]. We have previously shown that O2- formation also rises in HD human cybrids following 
exposure to 3-nitropropionic acid or staurosporine [43]. In this work, insulin and IGF-1 decreased 
mitochondrial O2- formation in mutant cells. Concomitantly, insulin and IGF-1 improved 
mitochondrial function, evaluated through increased mitochondrial membrane potential, in a PI-
3K/Akt-dependent manner in HD striatal cells. Enhanced mitochondrial function induced by the 
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peptides might be also related with reduced mitochondrial fragmentation in cells expressing 
mHtt. Indeed, we showed that insulin or IGF-1 treatment decreased p-Drp1/Drp1 levels. mHtt 
was previously described to bind Drp1, increasing its activity [62,63]. Increased Drp1 mRNA and 
protein levels were also found in the cortex and striatum of HD patients [9] in a grade-dependent 
manner [95]. We show here that MEK/Erk1/2 inhibition by U1026 greatly improved 
mitochondrial membrane potential, and enhanced IGF-1-induced increased mitochondrial 
membrane potential in mutant cells. Phosphorylated/active Erk was also increased in 
mitochondria of mutant cells. Recently, Erk was shown to phosphorylate and activate Drp1 
resulting in increased mitochondrial fission [34], and to directly phosphorylate Tfam 
downregulating mitochondrial transcription [37]. 
It was previously described that Akt can accumulate in mitochondria in its active state [96], 
promoting increased expression and activity of complex I, inducing anaerobic glycolysis and 
mitochondrial respiration, directly phosphorylating  and  subunits of ATP synthase and thus 
increasing its activity [35] and evoking neuroprotection [36]. Importantly, treatment with insulin 
and IGF-1 increased mitochondrial p-(Thr308)Akt and total Akt levels in both striatal cells. Akt 
may phosphorylate HKII at Thr473, increasing HKII association with mitochondria [67], while 
Hsp60 directly interacts with Akt1 resulting in its activation [68]. Although IGF-1 significantly 
rose HKII levels in mitochondria of wild-type cells, mitochondrial Hsp60 levels were enhanced 
in both striatal cells, suggesting that IGF-1 might promote the refolding of stress-induced 
denatured proteins in mutant cells.  
It was recently shown that mitochondrial protein import is inhibited by mHtt leading to 
neuronal death [97]. Here we show that mitochondrial levels of Tom20 and Tom40 are 
significantly enhanced by insulin in HD striatal cells, suggesting that the peptide may promote 
increased recognition, movement and import of cytosolically synthesized mitochondrial proteins. 
Tfam is required for mtDNA transcription and replication. In HD, polymorphisms in NRF-1 and 
Tfam were shown to be associated with age at onset in HD [98]. A reduction in Tfam levels in 
brain lysates from HD patients was previously found [95]. We showed decreased Tfam levels in 
HD lymphoblasts [84] and in mitochondria of mutant cells, suggesting that mHtt impairs mtDNA 
transcription and replication. Treatment with IGF-1, in particular, and insulin enhanced Tfam 
levels in mitochondria of mutant cells, underlying enhanced mtDNA transcription. Indeed, we 
detected increased levels of MT-COII in HD striatal cells upon treatment with IGF-1 and insulin. 
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The fact that insulin and IGF-1 might have mtDNA as a selective target in mutant cells via 
increased Tfam is consistent with the observation of unchanged NDUFS3, a nuclear-encoded 
subunit of complex I. 
Although the role of Akt in mitochondria is not completely understood, active mitochondrial 
Akt has been shown to be neuroprotective [36]. Therefore, a better knowledge about the role of 
Akt in mitochondria of HD striatal cells might be essential to describe the role of insulin and 
IGF-1 on mitochondrial function. 
In summary, our results show that insulin and IGF-1 (at low nM) activated cytosolic and 
mitochondrial Akt and inhibited Erk; this was accompanied by reduced p-Drp1/Drp1, suggesting 
reduced mitochondrial fission, and enhanced mitochondrial membrane potential in a process 
dependent on PI-3K/Akt signaling. Insulin and IGF-1 treatment further reduced mitochondrial 
ROS production and normalized mitochondrial SOD activity. Enhanced mitochondrial Tfam 
further underlay enhanced MT-COII levels in mitochondria of mutant cells, implicating increased 
function of the mitochondrial respiratory chain. Thus, insulin- and/or IGF-1-mediated 
intracellular PI3K/Akt signaling pathways may ameliorate mitochondrial function and ROS 
generation precluding apoptotic cell death in HD. 
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Figure legends 
Figure 1. Insulin and IGF-1 protect from mitochondrial ROS formation in HD striatal cells. 
Mitochondrial superoxide anion (O2-) formation measured with (A) MitoSOX Red and (B) DHE 
in wild-type and mutant striatal cells. (A) Cells were exposed to insulin or IGF-1 (0.1 nM) during 
24 h. (B) Intracellular O2- formation was further analysed following exposure to mitochondrial 
complex I (rotenone) and III (antimycin A) inhibitors (10 μM, for 1h). Data are the mean ± 
S.E.M. of 3-6 independent experiments. Statistical analysis: +++P<0.0001 when comparing 
mutant versus wild-type cells by Student’s t-test; ***P<0.0001 by two-way ANOVA for multiple 
groups using Bonferroni as post-hoc test, when comparing mutant versus wild-type cells; or 
##P<0.01 and ###P<0.0001 by two-way ANOVA when comparing treated versus non-treated 
(control) cells. 
 
Figure 2. Insulin and IGF-1 protect from caspase-3 activation and nuclear irregularities in 
HD striatal cells. (A) Caspase-3 activity in wild-type and mutant cells was tested following 
exposure to insulin or IGF-1 (0.1 nM) during 24h. Apoptotic or senescent nuclei was also 
analysed in (B) wild-type or (C) mutant striatal cells following incubation with insulin or IGF-1 
(0.1 nM) during 24h. Data are the mean ± S.E.M. of 4 independent experiments. Statistical 
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analysis: **P<0.01 and ***P<0.0001 by two-way ANOVA for multiple groups using Bonferroni as 
post-hoc test, when comparing mutant versus wild-type cells; #P<0.05, ##P<0.01 and ###P<0.0001 
by two-way ANOVA when comparing treated versus non-treated (control) cells, §P<0.05, 
§§P<0.01 and §§§P<0.0001 by one-way ANOVA using Bonferroni as post-hoc test when 
comparing normal treated nuclei versus apoptotic or senescent treated nuclei. 
 
Figure 3. Insulin and IGF-1 restored mitochondrial SOD activity in HD striatal cells. (A) 
Total and (B) mitochondrial SOD2 (Mn-SOD) activities in wild-type and mutant striatal cells. 
(C) Ac(Lys68)SOD2/SOD2 ratio and (D) SOD2 protein levels were measured after incubation 
with insulin or IGF-1 (0.1 nM, for 24 h). (E) Total and (F) mitochondrial SOD1 (Cu/Zn-SOD) 
activities and (G) SOD1 protein levels were measured in wild-type and mutant cells. In (H) 
mitochondrial SOD1/2 activity was analysed in striatal cells subjected to insulin or IGF-1 (0.1 
nM, for 24 h). Data are the mean ± S.E.M. of 3-4 independent experiments. Statistical analysis: 
+++P<0.0001 by Student’s t-test comparing mutant versus wild-type cells; tP<0.05 by Student’s t-
test comparing treated versus non-treated conditions; *P<0.05, **P<0.01 and ***P<0.0001 by two-
way ANOVA when comparing mutant versus wild-type cells; ##P<0.01 and ###P<0.0001 by two-
way ANOVA when comparing treated versus non-treated (control) cells. 
 
Figure 4. Insulin increases GCLc protein levels in mutant cells. (A,B) GCLc protein levels in 
wild-type and mutant striatal cells exposed to 0.1 and 1 nM (A) insulin or (B) IGF-1 (24h-
treatment). (C) GSH and (D) GSSG levels were analysed in both striatal cells after exposure to 
insulin or IGF-1 (0.1 nM). Data are the mean ± S.E.M. of 4 independent experiments. Statistical 
analysis: *P<0.05, **P<0.01 and ***P<0.0001 by two-way ANOVA when comparing mutant 
versus wild-type cells; #P<0.05 and ##P<0.01 by two-way ANOVA when comparing treated 
versus non-treated (control) cells.
 
Figure 5. Insulin and IGF-1 increase nuclear levels of phosphorylated Nrf2 in mutant cells. 
Striatal cells were treated with 0.1 nM insulin or IGF-1 during 24 h or 500 μM H2O2 during 3 h 
for determination of cellular (A,B) p-(Ser40)Nrf2/Nrf2 and nuclear (C,D) p-(Ser40)Nrf2/Nrf2 
levels and (E) Nrf2/ARE transcriptional activity by the luciferase reporter assay. Representative 
blots for (B) cellular p-Nrf2, Nrf2 and actin, or (D) nuclear p-Nrf2, Nrf2 and TBP. Results are the 
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mean ± S.E.M. of 3-7 independent experiments. Statistical analysis: +++P<0.0001 by Student’s t-
test comparing mutant versus wild-type cells; tP<0.05 and ttP<0.01 by Student’s t-test comparing 
treated versus non-treated conditions. ***P<0.0001 by two-way ANOVA when comparing mutant 
versus wild-type cells; #P<0.05 and ##P<0.01 by two-way ANOVA when comparing treated 
versus non-treated (control) cells. 
 
Figure 6. Insulin and IGF-1 promote Akt activation and Erk inhibition in HD striatal cells. 
Wild-type and mutant striatal cells were treated with 0.1 nM insulin or IGF-1 during 24 h for 
determination of cytosolic (A,C) p-(Thr308)Akt/Akt, (B,C) Akt/actin, and cellular (D,F) p-
(Thr202/Tyr204)Erk1/2, and (E,F) Erk/actin ratio. Representative blots for (C) p-(Thr308)Akt, 
Akt, and actin, and (F) p-(Thr202/Tyr204)Erk1/2, Erk1/2 and actin. Data are the mean ± S.E.M. 
of 3-4 independent experiments. Statistical analysis: +P<0.05 and ++P<0.01 by Student’s t-test 
comparing mutant versus wild-type cells; tP<0.05 and tttP<0.0001 by Student’s t-test comparing 
treated versus non-treated conditions. **P<0.01 by two-way ANOVA when comparing mutant 
versus wild-type cells; #P<0.05, ##P<0.01 and ###P<0.0001 by two-way ANOVA when 
comparing treated versus non-treated (control) cells. 
 
Figure 7. Insulin, IGF-1 and U126 increase mitochondrial membrane potential in HD 
striatal cells. (A-E) Wild-type and mutant striatal cells were treated with 0.1 nM insulin or IGF-
1, during 24h, for determination of mitochondrial levels of (A,C) p-(Ser616)Drp1/Drp1 and 
(B,C) Drp1, and (D-I) mitochondrial membrane potential using TMRM+. (C) Representative 
blots of mitochondrial fractions labelled for pDrp1, Drp1, SDHA (used to normalize data for 
mitochondrial proteins), and Nrf2 (used as a cytosolic and nuclear protein to verify the purity of 
mitochondrial fractions). In E the cells were exposed to 500 μM H2O2 during 3 h. Wild-type 
(F,H) or mutant (G,I) striatal cells were also incubated in the absence or presence of 25 μM 
LY294002, a PI-3K/Akt inhibitor (F,G) or 10 μM U0126, an inhibitor of MEK/Erk activity (H,I) 
during 24 h. Data are the mean ± S.E.M. of 4-8 independent experiments. Statistical analysis: 
+++P<0.0001 by Student’s t-test comparing mutant versus wild-type cells; tP<0.05 by Student’s t-
test comparing treated versus non-treated conditions; *P<0.05 and ***P<0.0001 by two-way 
ANOVA when comparing mutant versus wild-type cells; #P<0.05 and ###P<0.0001 by two-way 
ANOVA when comparing treated versus non-treated (control) cells.  @P<0.05 and @@@P<0.0001 
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by one-way ANOVA when comparing treated versus non-treated (control) cells. §P<0.05 and 
§§§P<0.0001 by one-way ANOVA when comparing insulin or IGF-1 versus LY294002 plus 
insulin or IGF-1 or insulin or IGF-1 versus U0126 plus insulin or IGF-1 treatment in both striatal 
cells.  
 
Figure 8. Insulin and IGF-1 enhance the levels of mitochondrial proteins involved in 
signaling, protein import and folding, mtDNA transcription and bioenergetics in HD 
striatal cells. Wild-type and mutant striatal cells were treated with 0.1 nM insulin or IGF-1, 
during 24 h, for analysis of several proteins in mitochondrial fractions, namely (A,L) p-
(Thr308)Akt, (B,L) Akt, (C,L) p-(Thr202/Tyr204)Erk1/2, (D,L) Erk1/2, (E,L) hexokinase type 
II (HKII), (F,L) heat shock 60kDa protein 1 (Hsp60), (G,L) translocase of outer mitochondrial 
membrane 20 homolog (yeast) (Tom20), (H,L) translocase of outer mitochondrial membrane 40 
homolog (yeast) (Tom40), (I,L) transcription factor A, mitochondrial (Tfam), (J,L) NADH 
dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa (NADH-coenzyme Q reductase) (NDUFS3) 
and (K,L) mitochondrial-encoded cytochrome c oxidase II (MT-COII). (L) Representative blots 
of proteins depicted in A-K, in which succinate dehydrogenase complex, subunit A, flavoprotein 
(Fp) (SDHA) was used to normalize data of other mitochondrial proteins; Nrf2 was used as a 
cytosolic and nuclear protein to verify the purity of mitochondrial fractions. Data are the mean ± 
S.E.M. of 4 independent experiments. Statistical analysis: ++P<0.01 and +++P<0.0001 by 
Student’s t-test comparing mutant versus wild-type cells; tP<0.05,  ttP<0.01, and tttP<0.0001 by 
Student’s t-test comparing treated versus non-treated conditions; *P<0.05, **P<0.01 and 
***P<0.0001 by two-way ANOVA when comparing mutant versus wild-type cells; #P<0.05, 
##P<0.01 and ###P<0.0001 by two-way ANOVA when comparing treated versus non-treated 
(control) cells. 
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Highlights: 
 
 Insulin/IGF-1 precludes mHtt-induced mitochondrial ROS formation and SOD activity. 
 Insulin/IGF-1 protection in HD cells is independent of Nrf2 transcription activity. 
 Insulin/IGF-1 enhances mitochondrial function via PI3K/Akt pathway in HD cells. 
 Insulin/IGF-1 increases p-Akt, Tfam and MT-COII in mitochondria of HD cells. 
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